Caleb Rans

Contributing Writer

Caleb Rans is a clinical pharmacist and medical communications specialist with professional expertise in medical writing, editing, and contract clinical research. He holds a PharmD from the University of Alberta and presently resides in Vancouver, Canada. He currently works as an independent consultant for several news, CME, and pharmaceutical companies.

All articles by Caleb Rans

Genitourinary Cancers Symposium

nsRPLND Appears Safe, Effective in Low-Volume Metastatic Seminoma

Caleb Rans

April 4, 2023

Nerve-sparing retroperitoneal lymph node dissection appears safe and effective for patients with low-volume metastatic seminoma.

Doctor escorting senior man down the hall

Genitourinary Cancers Symposium

Talabostat Plus Pembrolizumab Exhibits Activity in mCRPC With SCNC Phenotype

Caleb Rans

March 21, 2023

Combination talabostat and pembrolizumab has shown antitumor activity in patients who have metastatic castration-resistant prostate cancer with small-cell neuroendocrine carcinoma phenotype.

Genitourinary Cancers Symposium

Imaging With ⁸⁹Zr-DFO-Girentuximab Identifies Clear Cell Renal Cell Carcinoma

Caleb Rans

March 16, 2023

A novel imaging technique, 89Zr-DFO-girentuximab PET/CT, can accurately and noninvasively identify clear cell renal cell carcinoma, a study suggests.

Genitourinary Cancers Symposium, News

Combo Shows Promise in High-Risk nmCRPC

Caleb Rans

March 10, 2023

Treatment with radiolabeled J591 plus ketoconazole and hydrocortisone may delay time to metastasis in patients with high-risk nmCRPC.

Genitourinary Cancers Symposium

Pembrolizumab Could Meet Unmet Need in BCG-Unresponsive High-Risk NMIBC

Caleb Rans

March 8, 2023

Pembrolizumab demonstrated antitumor activity in patients with high-risk, papillary NMIBC who did not undergo radical cystectomy and did not respond to BCG.

Genitourinary Cancers Symposium

No Benefit With Longer Course of ADT in Localized, High-Risk Prostate Cancer

Caleb Rans

March 2, 2023

A longer course of androgen deprivation therapy does not improve outcomes in patients with localized, high-risk prostate cancer receiving I-125 brachytherapy and external beam radiotherapy, a phase 3 trial suggests.

Genitourinary Cancers Symposium

Olaparib Plus Abiraterone Produces Longest Median OS to Date in First-Line mCRPC Setting

Caleb Rans

February 28, 2023

Adding olaparib to first-line treatment with abiraterone extends overall survival in patients with metastatic castration-resistant prostate cancer, a phase 3 study suggests.

Genitourinary Cancers Symposium

Niraparib Improves rPFS in BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

Caleb Rans

February 27, 2023

Adding niraparib to AAP improves rPFS in patients with BRCA-mutated metastatic castration-resistant prostate cancer, a phase 3 trial suggests.

Next post in Genitourinary Cancers Symposium